Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 5/20 | 0.47 |
| ▸ | CHRND | Q07001 | 5/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6290997 | 0.90 | CALCRL (0.47) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Trifluoroacetic Acid SCHEMBL6286376 | 0.85 | CALCRL (0.46) | CALCRLGRIA1NPY1RITGB3ITGA2B | |
| SCHEMBL7037682 | 0.83 | CALCRL (0.49) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Trifluoroacetic Acid SCHEMBL6286184 | 0.83 | ANPEP (0.41) | CALCRLCHRNDCHRNA1CHRNGCHRNB1 | |
| Trifluoroacetic Acid SCHEMBL6286278 | 0.83 | CALCRL (0.47) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Trifluoroacetic Acid SCHEMBL6288016 | 0.83 | CALCRL (0.47) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL7108336 | 0.82 | CHRND (0.49) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Hydrochloric Acid SCHEMBL6287172 | 0.82 | CHRND (0.49) | CALCRLGRIA1CHRNDCHRNA1CHRNG | |
| Trifluoroacetic Acid SCHEMBL6282751 | 0.80 | HPGDS (0.48) | — | |
| Hydrochloric Acid SCHEMBL6291010 | 0.80 | CALCRL (0.50) | CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | CALCRL 464/4885GRIA1 2157/4885CHRND 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.